• CD28 targeting
  • How it works
TV Léman Bleu SA l Interview with Nicolas Fischer

TV Léman Bleu SA l Interview with Nicolas Fischer


22nd program of "Le Monde de Demain" dedicated to biotechnologies.

GENEVA, SWITZERLAND/ LE MONDE DE DEMAIN/ MARCH 30, 2021 /

TV Léman Bleu SA presents "Le monde de Demain", a series of programs will take the public to the heart of industrial and technological companies, to discover the savoir-faire, the diversity of professions and the talents of companies at the cutting edge of the sector and leaders in their field.

In this 22nd program, "Le monde de Demain" makes you discover biotechnology:

  • Interview with the CEO of Light Chain Biosciense, Nicolas Fischer.

  • Epithelix - Provider of cells, 3D tissues and testing services.

  • GeNeuro SA - Focus on Human Endogenous Retroviruses (#HERVs) to fight the progression of disability in #MultipleSclerosis $GNRO

See full [VIDEO] FRENCH :

tv leman bleu sa l interview with nicolas

TV Léman Bleu SA
41b, route des Jeunes
1227 Carouge

022 309 43 21
SOURCE: OPI, Office de Promotion des Industries et des Technologies

New publication in Cancer Immunology Research

NI-3201 Is a Bispecific Antibody Mediating PD-L1–Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

Read more

LinkedIn